Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRNA | Common Stock | Options Exercise | $61.1K | +5K | $12.21* | 5K | Aug 6, 2021 | Direct | F1 | |
transaction | MRNA | Common Stock | Sale | -$2.05M | -5K | -100% | $410.30 | 0 | Aug 6, 2021 | Direct | F1 |
transaction | MRNA | Common Stock | Options Exercise | $61.1K | +5K | $12.21* | 5K | Aug 9, 2021 | Direct | F1 | |
transaction | MRNA | Common Stock | Sale | -$2.06M | -5K | -100% | $411.50 | 0 | Aug 9, 2021 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -5K | -1.32% | $0.00 | 375K | Aug 6, 2021 | Common Stock | 5K | $12.21 | Direct | F1, F2 |
transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -5K | -1.33% | $0.00 | 370K | Aug 9, 2021 | Common Stock | 5K | $12.21 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021. |
F2 | 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. |
Chief Technical Operations and Quality Officer